Alogabat
 | |
| Clinical data | |
|---|---|
| Other names | GABA-Aa5 PAM; GABA-Aα5 PAM; RG-7816; RG7816; RO-7017773; RO7017773 |
| Routes of administration | Oral[1] |
| Drug class | α5 subunit-containing GABAA receptor positive allosteric modulator |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| KEGG | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C21H23N5O4 |
| Molar mass | 409.446 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Alogabat (INN, USAN; developmental code names RG-7816 and RO7017773) is an α5 subunit-containing GABAA receptor positive allosteric modulator which is under development for the treatment of pervasive developmental disorders (e.g., autism) and Angelman syndrome.[1][2][3][4] It is taken by mouth.[1]
As of June 2024, alogabat is in phase 2 clinical trials for pervasive developmental disorders and Angelman syndrome.[1][2] It is under development by Roche.[1][2]
See also
[edit]References
[edit]- ^ a b c d e "Alogabat - Genentech". AdisInsight. 28 June 2024. Retrieved 29 October 2024.
- ^ a b c "Delving into the Latest Updates on RG-7816 with Synapse". Synapse. 19 September 2024. Retrieved 29 October 2024.
- ^ Maramai S, Benchekroun M, Ward SE, Atack JR (April 2020). "Subtype Selective γ-Aminobutyric Acid Type A Receptor (GABAAR) Modulators Acting at the Benzodiazepine Binding Site: An Update". Journal of Medicinal Chemistry. 63 (7): 3425–3446. doi:10.1021/acs.jmedchem.9b01312. PMID 31738537.
- ^ Stevens EB, Stephens GJ (2024). "Ion Channels as Targets in Drug Discovery: Outlook and Perspectives". Ion Channels as Targets in Drug Discovery. Cham: Springer International Publishing. p. 1–34. doi:10.1007/978-3-031-52197-3_1. ISBN 978-3-031-52196-6.
 | This drug article relating to the nervous system is a stub. You can help Wikipedia by expanding it. |